Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Oct;96(10):1560-4.
doi: 10.3324/haematol.2011.046417.

The levels of IL-17A and of the cytokines involved in Th17 cell commitment are increased in patients with chronic immune thrombocytopenia

Affiliations

The levels of IL-17A and of the cytokines involved in Th17 cell commitment are increased in patients with chronic immune thrombocytopenia

Andreia Maria Camargos Rocha et al. Haematologica. 2011 Oct.

Abstract

Th17 cells have been associated with immune-mediated diseases in humans but it has still not been determined whether they play a role in immune thrombocytopenia. We evaluated representative cytokines of the Th17, Th1, Th2 and Treg cell commitment in the serum of patients with chronic immune thrombocytopenia, as well as the cell source of IL-17A. Higher levels of IL-17A and Th17-related cytokines, and an increased percentage of IL-17A producing CD4+ and neutrophils were observed in patients. The levels of cytokines involved in Th1 cell commitment IFN-γ, IL-2, IL12-p70 and the percentages of Th1 cells were also increased, but IL-4 was not detected. Although the concentrations of IL-10 were higher, the levels of TGF-β were similar in both groups. In conclusion, our results point to a putative role for Th-17 cells/IL-17A cytokine in the pathogenesis of chronic immune thrombocytopenia.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Box plots representing the serum levels (pg/mL) of IL-1β, IL-2, IL-6, IL-10, IL-12p70, IL-17, IL-23, IFN-γ, TGF-β and TNF-α in patients with chronic immune thrombocytopenia (n=98) and controls (n=150). The upper and lower limits of the boxes represent the 75th and 25th percentiles, respectively; the horizontal bar across the box indicates the median and the ends of the vertical lines indicate the minimum and maximum data values. *P<0.001.
Figure 2.
Figure 2.
Circulating percentage of Th17 and Th1 cells and neutrophils expressing IL-17A. (A) IL-17A and IFN-γ expression in CD4 T cells and IL17A in neutrophils. Representative dot plots from controls and patients (cITP). The gates used for determining the percentage of cytokine expression in the cell populations are shown. (B) Box plots representing the percentage of circulating CD4+ IL-17, CD4+ IFN-γ and neutrophils IL-17 in patients with chronic immune thrombocytopenia and controls. The upper and lower limits of the boxes represent the 75th and 25th percentiles, respectively; the horizontal bar across the box indicates the median and the ends of the vertical lines indicate the minimum and maximum data values. *P=0.001; **P=0.04 and ***P=0.05.

References

    1. Stasi R, Evangelista ML, Stipa E, Buccisano F, Venditti A, Amadori S. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb Haemost. 2008;99(1):4–13. - PubMed
    1. McMillan R. Antiplatelet antibodies in chronic Immune Thrombocytopenia and their role in platelet destruction and defective platelet production. Hematol Oncol Clin North Am. 2009;23(6):1163–75. - PubMed
    1. Semple JW, Milev Y, Cosgrave D, Mody M, Hornstein A, Blanchette V, et al. Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T cell-reactivity. Blood. 1996;87(10):4245–54. - PubMed
    1. Zhou B, Zhao H, Yang RC, Han ZC. Multi-dysfunctional pathophysiology in ITP. Crit Rev Oncol Hematol. 2005;54(2):107–16. - PubMed
    1. Olsson B, Andresson PO, Jernas M, Jacobsson S, Carlsson B, Carlsson LMS, et al. T-cell mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med. 2003;9(9):1123–4. - PubMed

Publication types